{
    "nct_id": "NCT06304636",
    "official_title": "Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "Inclusion Criteria\n\n* Patients must be 18 years of age or older at the time of enrollment.\n* Patients must be diagnosed with active and measurable relapsed/refractory multiple myeloma.\n* Patients must have failed at least 3 prior lines of therapy which must have included an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug or biologic. Failure of treatment and measurable myeloma disease are defined as per 2016 IMWG criteria.\n* Patients must have clinical performance status of ECOG 0-2.\n* Patients must have adequate vital organ function as defined by:\n* Hemoglobin ≥8 g/dL\n* Absolute neutrophil count > 1000/ mm3\n* Platelets > 50,000/mm3\n* ALT/AST levels lower than 3-fold of normal\n* Creatinine clearance ≥45 mL/min/1.73 m2\n* Normal cardiac and pulmonary function\n* No thromboembolic events in the past 3 months\n* No heparin allergy or active infection\n\nExclusion Criteria\n\n* Patients who have any active and uncontrolled infection.\n* Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above 40 mg/day prednisone equivalent).\n* Patients who have active central nervous system disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}